Summary of post-treatment CAPS score changes from clinical trials with psychotherapies. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment disease course measures from clinical trials with psychotherapies. by Filip Stanicic (17808254)

Subjects:

Percentage reduction (mean (±SD)) of RMNPI values (Δ%RMNPI) after brushing in selected areas. by Nadine Schlueter (755050)

Subjects:

Survival function analysis of mortality for Viral load status and Treatment Interruption status. by Ekerette Emmanuel Udoh (7326194)

Subjects:

Survival function analysis of treatment Interruption for Viral load status and BMI status. by Ekerette Emmanuel Udoh (7326194)

Subjects:

Survival function analysis of viral suppression for BMI status and Treatment Interruption status. by Ekerette Emmanuel Udoh (7326194)

Subjects:

Ectopic lesions are decreased in PUGKO mice compared to controls. by Jan Sunde (8837384)

“…PG treatment in PUGKO mice decreases the expression of FOXA2 almost 33 times compared to the non-PG TX mice. …”

Mechanical data for the two drill bits in the MIPS system (MIPS GS, MIPS WD) and the single drill bits in the MONO system at different feed rates (mm/s). The data are shown as the... by Marsel Ganeyev (21453399)

Subjects:

MiR-129-5p levels were decreased in mouse depression models. by Qiaozhen Qin (13159201)

“…(n = 3 - 10 mice per group; Data are presented as the mean ± standard error; *, **, ***, and **** indicate significance at p < 0.05, p < 0.01, p < 0.001, and p < 0.0001, respectively.).…”

Arm tremor and rigidity during settings (mean ± sd). by Verneri Ruonala (12419145)

Subjects:

Evogliptin attenuates the phenotypic switch of VSMCs during CER treatment by decreasing the osteogenesis-associated genes <i>in-vitro.</i> by Razia Rashid Rahil (22772495)

“…Results are presented as mean ± SD. Ceramide: CER, Evogliptin: EVO. *(P < 0.05) significant vs. control group; ^$(P < 0.05) significant vs. …”

Lists of differentially expressed genes for the interaction between high night-time temperature and 1-MCP treatments. by Wardah K. Mustahsan (17484456)

Subjects:

Mast cell density and tactile sensitivity decreased after 10 preventative imatinib treatments followed by repeated MI challenges. by Jaclyn M. Kline (9565161)

“…(B) Tactile sensitivity in sensitized mice preventatively treated with imatinib or NT and then 10 daily MI challenges. Results reported as mean ± SEM of the percent decrease from baseline in the withdrawal threshold for each treatment group, n = 18/treatment group. …”

Summary of post-treatment CAPS score changes from clinical trials with FDA-approved medications. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment disease course measures from off-label medications clinical trials. by Filip Stanicic (17808254)

Subjects:

Post-treatment CAPS score changes from clinical trials with off-label PTSD medications. by Filip Stanicic (17808254)

Subjects:

Annual incidence rate per 100 person-years trend for ART treatment outcomes. by Ekerette Emmanuel Udoh (7326194)

Subjects:

Treatment and outcome characteristics. by Manik Chhabra (10822587)

Subjects:

Significant interactions from mixed linear models of ECM colonization (Table 1). by Laura García de Jalón (8939456)

Clinical and laboratory measurements of patients with ALS (N = 13; Mean±SD; ns = not significant; nd = not determined; * = evidence of subgroup responsiveness). by Ann Logan (9361)